Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DNLI

Denali Therapeutics Inc

Dec 26 • 09:37AM ET

16.87

-0.12 -0.69 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN ALNY UTHR IONS MRNA SRPT NBIX VRTX PTCT

| Held by: VTI IWM XBI VB VBK VXF IWN IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.91	Insider Own	11.01%	Shs Outstand	146.63M	Perf Week	0.61%
Market Cap	2.63B	Forward P/E	-	EPS next Y	-2.84	Insider Trans	-2.84%	Shs Float	138.96M	Perf Month	-11.80%
Enterprise Value	1.83B	PEG	-	EPS next Q	-0.75	Inst Own	89.31%	Short Float	9.42%	Perf Quarter	20.95%
Income	-498.74M	P/S	-	EPS this Y	-16.43%	Inst Trans	1.34%	Short Ratio	7.90	Perf Half Y	19.67%
Sales	0.00M	P/B	2.67	EPS next Y	5.12%	ROA	-39.75%	Short Interest	13.09M	Perf YTD	-17.21%
Book/sh	6.32	P/C	3.11	EPS next 5Y	1.04%	ROE	-44.44%	52W High	24.34 -30.69%	Perf Year	-18.80%
Cash/sh	5.43	P/FCF	-	EPS past 3/5Y	-2.44% -4.46%	ROIC	-51.87%	52W Low	10.57 59.63%	Perf 3Y	-38.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.93% 5.11%	Perf 5Y	-80.29%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.30%	Oper. Margin	-	ATR (14)	0.86	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.79	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	44.77	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	9.79	EPS Q/Q	-16.35%	SMA20	-6.19%	Beta	1.03	Target Price	32.21
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	-2.07%	Rel Volume	0.19	Prev Close	16.99
Employees	422	LT Debt/Eq	0.04	Earnings	Nov 06 AMC	SMA200	12.03%	Avg Volume	1.66M	Price	16.87
IPO	Dec 08, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.03% -100.00%	Trades		Volume	21,204	Change	-0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight	$41 → $33
Feb-11-25	Initiated	Deutsche Bank	Buy	$31
Jan-07-25	Initiated	Robert W. Baird	Outperform	$31
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy	$37
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy	$32
Nov-20-23	Resumed	JP Morgan	Overweight	$28
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$85 → $35
Sep-06-23	Initiated	B. Riley Securities	Buy	$38
Jan-30-23	Initiated	SVB Securities	Outperform	$50
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy	$38
Nov-02-22	Initiated	BofA Securities	Buy	$40
Jun-23-22	Initiated	Berenberg	Buy	$39
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform	$85
Sep-01-21	Initiated	SMBC Nikko	Outperform	$78

Show Previous Ratings

Dec-22-25 06:11AM	Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? (Insider Monkey)
Dec-10-25 04:58PM	Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More (Motley Fool) -10.63%
12:14AM	Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-09-25 04:01PM	Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
05:00AM	Loading…
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 07:00AM	Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement (GlobeNewswire) +5.84%
Nov-10-25 08:19PM	H.C. Wainwright Reiterates "Buy" Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results (Insider Monkey) +12.69%
Nov-07-25 01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
Nov-06-25 04:01PM	Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
04:00PM	Denali Therapeutics Announces Board and Executive Leadership Updates (GlobeNewswire)
Oct-14-25 08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
07:53AM	AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance (BioPharma Dive)
Oct-13-25 04:01PM	Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Sep-10-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? (Zacks)
08:18AM	Loading…
Aug-12-25 08:18AM	DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 (Zacks) -5.03%
Aug-11-25 04:01PM	Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-25 05:15AM	Clinical trial supply chains in the US navigate pharma tariffs (Clinical Trials Arena)
Aug-05-25 09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-31-25 11:58AM	Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy (Insider Monkey)
Jul-30-25 08:55AM	Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue? (Zacks)
Jul-17-25 08:15AM	Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Companys Board of Directors (GlobeNewswire)
Jul-16-25 09:38AM	BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target (Insider Monkey)
Jul-08-25 09:59AM	DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review (Zacks)
Jul-07-25 08:00AM	Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) (GlobeNewswire)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-05-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? (Zacks)
May-07-25 01:10PM	Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus (Zacks)
May-06-25 04:01PM	Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome (GlobeNewswire) -12.63%
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
01:20PM	Loading…
May-02-25 01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
Apr-29-25 06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-03-25 09:32AM	DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up (Zacks) -6.91%
Apr-02-25 08:00AM	Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program (GlobeNewswire) +11.80%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 02:16PM	Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (SeekingAlpha)
08:57AM	Why You Shouldn't Bet Against Denali (DNLI) Stock (Zacks)
Mar-04-25 08:00AM	Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer (TipRanks)
Mar-03-25 12:49PM	Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos Investments in 2025? (Insider Monkey) -8.21%
Feb-27-25 04:01PM	Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) -10.97%
Feb-06-25 11:42AM	Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa (GlobeNewswire)
Jan-30-25 08:00AM	Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium (GlobeNewswire)
Jan-17-25 11:18AM	Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-13-25 08:00AM	Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire)
Jan-08-25 08:00AM	Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) (GlobeNewswire)
07:25AM	Denali Therapeutics price target lowered to $32 from $35 at BTIG (TipRanks)
Jan-07-25 04:33PM	These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com) +6.86%
04:08PM	Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment (Investor's Business Daily)
02:16PM	These Stocks Are Moving the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com)
12:48PM	Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected (Benzinga)
10:13AM	Denali Therapeutics Phase II/III trial of ALS therapy fails to meet primary endpoint (Clinical Trials Arena)
10:13AM	Denali Therapeutics ALS therapy fails to meet primary endpoint in Phase II/III trial (Clinical Trials Arena)
09:33AM	Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. (Investor's Business Daily)
04:41AM	ALS drugs from Denali, Calico come up short, marking setback for Healey trial (BioPharma Dive)
Jan-06-25 04:30PM	Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire) -6.77%
Jan-03-25 01:08PM	Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic (Benzinga)
Dec-17-24 06:25AM	Denali Therapeutics upgraded to Buy from Hold at Stifel (TipRanks)
Dec-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? (Zacks) +6.73%
Dec-05-24 08:00AM	Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease (GlobeNewswire)
Nov-06-24 04:01PM	Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.87%
Oct-29-24 10:01AM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-13-24 04:56PM	Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Sep-16-24 11:22AM	Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? (Zacks)
Sep-04-24 08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 08:00AM	Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Aug-19-24 10:13AM	Genetic testing in Parkinsons disease patients: a standard of care imperative? (Medical Device Network)
Aug-14-24 02:00PM	Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration (GlobeNewswire)
Aug-06-24 09:55AM	Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade (Zacks)
Aug-01-24 06:45AM	Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-23-24 06:13AM	Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? (Zacks)
Jul-16-24 03:19PM	Denali Therapeutics Stock Gets Technical Rating Upgrade (Investor's Business Daily)
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-28-24 08:37AM	Denali (DNLI) Outperforms Industry in 3 Months: Here's Why (Zacks)
Jun-24-24 09:07AM	Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last? (Zacks)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
Jun-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report? (Zacks)
Jun-04-24 01:17PM	Denali's (DNLI) Candidate Selected for FDA's START Pilot Program (Zacks)
Jun-03-24 08:00AM	Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies (GlobeNewswire) +9.81%
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-08-24 11:17AM	Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating (MT Newswires) +12.17%
09:16AM	Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating (MT Newswires)
08:20AM	Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus (Zacks)
May-07-24 10:56PM	DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:56PM	Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts (GuruFocus.com)
04:01PM	Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-01-24 08:00AM	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire)
Apr-09-24 08:46AM	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick (Zacks)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 11:30AM	Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? (Zacks)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Feb-28-24 08:08AM	Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) -13.45%
Feb-27-24 08:31AM	Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +38.25%
08:05AM	Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Denali Therapeutics Announces $500 million Private Placement Equity Financing (GlobeNewswire)
06:53AM	Denali, fresh off study setback, gets $500M lift (BioPharma Dive)
Feb-16-24 08:39AM	UPDATE 2-Denali-Sanofi's ALS drug fails to meet mid-stage trial goal (Reuters) -7.30%
08:22AM	Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial (Reuters)
07:13AM	ALS drug from Denali, Sanofi falls short in mid-stage study (BioPharma Dive)
Feb-07-24 08:00AM	Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium (GlobeNewswire)
Feb-01-24 08:00AM	Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium (GlobeNewswire)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CAROLE HO	Officer	Dec 04 '25	Proposed Sale	19.00	1,882	35,758		Dec 04 04:41 PM
Schuth Alexander O.	COFO and Secretary	Aug 12 '25	Sale	13.58	2,937	39,884	242,346	Aug 14 08:33 PM
Ho Carole	Chief Medical Officer	Aug 12 '25	Sale	13.58	2,937	39,884	217,391	Aug 14 08:33 PM
Ho Carole	Chief Medical Officer	Aug 13 '25	Sale	14.64	806	11,800	216,585	Aug 14 08:33 PM
CAROLE HO	Officer	Aug 13 '25	Proposed Sale	13.22	806	10,655		Aug 13 04:45 PM
Schuth Alexander O.	Officer	Aug 12 '25	Proposed Sale	13.58	2,937	39,876		Aug 12 08:46 PM
Ho Carole	Officer	Aug 12 '25	Proposed Sale	13.58	2,937	39,876		Aug 12 08:44 PM
Ho Carole	Chief Medical Officer	Aug 05 '25	Option Exercise	0.68	44,655	30,365	220,328	Aug 07 05:34 PM
Watts Ryan J.	President and CEO	Jul 09 '25	Option Exercise	1.05	495,282	520,792	748,353	Jul 11 05:13 PM
Watts Ryan J.	President and CEO	Jul 09 '25	Sale	15.00	495,282	7,429,230	253,071	Jul 11 05:13 PM
Watts Ryan J.	Officer	Jul 09 '25	Proposed Sale	14.33	495,282	7,097,391		Jul 09 04:13 PM
Ho Carole	Chief Medical Officer	Jan 06 '25	Sale	20.22	12,255	247,796	178,580	Jan 08 08:26 PM
Ho Carole	Chief Medical Officer	Jan 07 '25	Sale	20.81	2,907	60,495	175,673	Jan 08 08:26 PM
Schuth Alexander O.	COFO and Secretary	Jan 06 '25	Sale	20.22	12,255	247,796	247,215	Jan 08 08:25 PM
Schuth Alexander O.	COFO and Secretary	Jan 07 '25	Sale	20.81	2,907	60,495	244,308	Jan 08 08:25 PM
Watts Ryan J.	President and CEO	Jan 06 '25	Sale	20.22	29,266	591,759	260,721	Jan 08 08:24 PM
Watts Ryan J.	President and CEO	Jan 07 '25	Sale	20.81	7,650	159,196	253,071	Jan 08 08:24 PM
Krognes Steve E.	Director	Jan 07 '25	Sale	20.81	3,339	69,485	25,757	Jan 08 08:23 PM
Ho Carole	Officer	Jan 07 '25	Proposed Sale	20.81	2,907	60,495		Jan 07 08:14 PM
Schuth Alexander O.	Officer	Jan 07 '25	Proposed Sale	20.81	2,907	60,495		Jan 07 08:12 PM
Watts Ryan J.	Director	Jan 07 '25	Proposed Sale	20.81	7,650	159,196		Jan 07 08:10 PM
Krognes Steve E.	Director	Jan 07 '25	Proposed Sale	20.81	3,339	69,485		Jan 07 08:08 PM
Schuth Alexander O.	Officer	Jan 06 '25	Proposed Sale	20.22	12,255	247,781		Jan 07 08:06 PM
Watts Ryan J.	Director	Jan 06 '25	Proposed Sale	20.22	29,266	591,723		Jan 07 08:03 PM
Ho Carole	Officer	Jan 06 '25	Proposed Sale	20.22	12,255	247,786		Jan 07 08:01 PM
SATO VICKI L	Director	Jan 02 '25	Sale	20.91	3,080	64,403	107,976	Jan 03 04:13 PM
VICKI LEE SATO	Director	Jan 02 '25	Proposed Sale	20.38	6,160	125,541		Jan 02 04:23 PM
Schuth Alexander O.	COFO and Secretary	Dec 27 '24	Option Exercise	5.28	6,708	35,418	205,290	Dec 31 04:18 PM
STEVE KROGNES	Director	Dec 31 '24	Proposed Sale	20.24	30,000	607,200		Dec 31 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DNLI

Denali Therapeutics Inc

Upgrade your FINVIZ experience